By growing mini‑organs from patient biopsy samples, we create high‑throughput drug screens tailored to each individual’s tumor or genetic disease. Integrated genomic and pharmacodynamic analyses will pinpoint optimal therapies. This approach seeks to streamline personalized treatment decisions in clinical settings.